Skip to main content
. 2018 Sep 24;21(4):781–789. doi: 10.1007/s11307-018-1262-3

Fig. 1.

Fig. 1.

Figure demonstrating regions of interest in the left humerus in a patient with clinical progressive disease. a, c [18F]FDG and b, d [18F]fluoride PET transaxial slices a, b before and c, d 8 weeks after treatment. [18F]FDG SUVmax 14.6 at baseline and 15.4 at 8 weeks. [18F]fluoride SUVmax 37.7 at baseline, 56.5 at 8 weeks and 82.4 at 12 weeks (not shown).